Regulated Psychedelics and Big Pharma: Can They Coexist?

In this thoughtful and wide-ranging conversation, Justin Botillier, CEO of Calyx CPA, sat down with Kevin Lanzo, Founder, Past President, and current Board Member of the Psychedelic Pharmacists Association (PPA), and Colby Burns, current President of the PPA, to explore the role of psychedelics in healthcare. The PPA, a nonprofit organization, is focused on bridging the gap between traditional plant-based medicine and Western medical practices through education and advocacy. Kevin and Colby discussed their efforts to integrate psychedelic therapies into mainstream healthcare by educating medical professionals and contributing to policy discussions at both the state and federal levels. They also addressed the current landscape in Oregon and Colorado, where state-regulated psilocybin service centers are beginning to emerge, noting both the opportunities and challenges of early adoption.

A significant portion of the conversation centered on the pharmaceutical industry’s growing interest in psychedelics. Kevin, who consults with psychedelic pharmaceutical companies, explained how treatments are being developed to fit episodic or recurring models, akin to antibiotics or ketamine therapy. The group also discussed concerns about potential monopolization, such as efforts by some companies to restrict access to only their synthetic versions of psilocybin. Justin raised valid concerns about the future of traditional and regulated models coexisting, and the importance of maintaining access to natural medicine and culturally grounded practices. Both Kevin and Colby emphasized the need for a diverse ecosystem of care that includes ceremonial and community-based approaches alongside medical ones.

The conversation concluded with a broader reflection on the future of healthcare. They discussed how psychedelics could challenge and reshape traditional models of medicine, encouraging more human-centered, holistic care. The limitations of current research tools were acknowledged, along with the importance of personal experience, spiritual insight, and community in the healing process. With the PPA exploring ways to support clinics, especially around safety and drug interaction screening, Kevin and Colby reiterated their commitment to helping the field grow responsibly. The shared hope was that psychedelics might not only be accepted by traditional medicine but help transform it for the better.